vs
Amphastar Pharmaceuticals, Inc.（AMPH）とIDACORP INC（IDA）の財務データ比較。上の社名をクリックして会社を切り替えられます
IDACORP INCの直近四半期売上が大きい（$360.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約2.0倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 12.1%、差は1.2%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -4.2%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-216.2M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -7.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
IDACORP, Inc.はアメリカ・アイダホ州に法人登録され、本社をボイシに置く電力持株会社です。1998年10月1日に設立され、傘下にアイダホパワー社、IDACORPフィナンシャル社、アイダウエストエナジー社を有し、電力供給、エネルギーサービス、関連金融事業を手がけています。
AMPH vs IDA — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $360.1M |
| 純利益 | $24.4M | $43.6M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 14.9% |
| 純利益率 | 13.3% | 12.1% |
| 売上前年比 | -1.8% | -4.2% |
| 純利益前年比 | -35.7% | 15.1% |
| EPS（希薄化後） | $0.51 | $0.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $360.1M | ||
| Q3 25 | $191.8M | $526.4M | ||
| Q2 25 | $174.4M | $449.3M | ||
| Q1 25 | $170.5M | $411.1M | ||
| Q4 24 | $186.5M | $375.9M | ||
| Q3 24 | $191.2M | $532.5M | ||
| Q2 24 | $182.4M | $442.6M | ||
| Q1 24 | $171.8M | $417.9M |
| Q4 25 | $24.4M | $43.6M | ||
| Q3 25 | $17.4M | $124.4M | ||
| Q2 25 | $31.0M | $95.8M | ||
| Q1 25 | $25.3M | $59.6M | ||
| Q4 24 | $38.0M | $37.9M | ||
| Q3 24 | $40.4M | $113.6M | ||
| Q2 24 | $37.9M | $89.5M | ||
| Q1 24 | $43.2M | $48.2M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 14.9% | ||
| Q3 25 | 13.2% | 27.5% | ||
| Q2 25 | 24.2% | 22.4% | ||
| Q1 25 | 21.9% | 13.4% | ||
| Q4 24 | 24.2% | 11.0% | ||
| Q3 24 | 29.8% | 25.1% | ||
| Q2 24 | 30.3% | 23.3% | ||
| Q1 24 | 27.9% | 11.9% |
| Q4 25 | 13.3% | 12.1% | ||
| Q3 25 | 9.0% | 23.6% | ||
| Q2 25 | 17.8% | 21.3% | ||
| Q1 25 | 14.8% | 14.5% | ||
| Q4 24 | 20.4% | 10.1% | ||
| Q3 24 | 21.1% | 21.3% | ||
| Q2 24 | 20.8% | 20.2% | ||
| Q1 24 | 25.1% | 11.5% |
| Q4 25 | $0.51 | $0.78 | ||
| Q3 25 | $0.37 | $2.26 | ||
| Q2 25 | $0.64 | $1.76 | ||
| Q1 25 | $0.51 | $1.10 | ||
| Q4 24 | $0.74 | $0.72 | ||
| Q3 24 | $0.78 | $2.12 | ||
| Q2 24 | $0.73 | $1.71 | ||
| Q1 24 | $0.81 | $0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $215.7M |
| 総負債低いほど良い | $608.7M | $3.3B |
| 株主資本純資産 | $788.8M | $3.6B |
| 総資産 | $1.6B | $10.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $215.7M | ||
| Q3 25 | $276.2M | $333.2M | ||
| Q2 25 | $231.8M | $474.5M | ||
| Q1 25 | $236.9M | $634.5M | ||
| Q4 24 | $221.6M | $368.9M | ||
| Q3 24 | $250.5M | $427.9M | ||
| Q2 24 | $217.8M | $169.6M | ||
| Q1 24 | $289.6M | $157.6M |
| Q4 25 | $608.7M | $3.3B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $3.1B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $3.6B | ||
| Q3 25 | $776.7M | $3.5B | ||
| Q2 25 | $757.5M | $3.4B | ||
| Q1 25 | $751.3M | $3.3B | ||
| Q4 24 | $732.3M | $3.3B | ||
| Q3 24 | $727.7M | $3.3B | ||
| Q2 24 | $713.3M | $3.2B | ||
| Q1 24 | $672.4M | $2.9B |
| Q4 25 | $1.6B | $10.2B | ||
| Q3 25 | $1.7B | $10.1B | ||
| Q2 25 | $1.6B | $9.9B | ||
| Q1 25 | $1.6B | $9.6B | ||
| Q4 24 | $1.6B | $9.2B | ||
| Q3 24 | $1.5B | $9.1B | ||
| Q2 24 | $1.5B | $8.7B | ||
| Q1 24 | $1.6B | $8.3B |
| Q4 25 | 0.77× | 0.93× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.92× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $137.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-216.2M |
| FCFマージンFCF / 売上 | 13.4% | -60.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 98.3% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 3.16× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-577.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $137.8M | ||
| Q3 25 | $52.6M | $162.8M | ||
| Q2 25 | $35.6M | $176.9M | ||
| Q1 25 | $35.1M | $124.3M | ||
| Q4 24 | $29.0M | $136.4M | ||
| Q3 24 | $60.0M | $201.9M | ||
| Q2 24 | $69.1M | $146.4M | ||
| Q1 24 | $55.3M | $109.7M |
| Q4 25 | $24.6M | $-216.2M | ||
| Q3 25 | $47.2M | $-127.9M | ||
| Q2 25 | $25.0M | $-156.4M | ||
| Q1 25 | $24.4M | $-77.0M | ||
| Q4 24 | $16.6M | $-48.9M | ||
| Q3 24 | $46.2M | $-16.1M | ||
| Q2 24 | $63.1M | $-199.6M | ||
| Q1 24 | $46.5M | $-150.3M |
| Q4 25 | 13.4% | -60.0% | ||
| Q3 25 | 24.6% | -24.3% | ||
| Q2 25 | 14.3% | -34.8% | ||
| Q1 25 | 14.3% | -18.7% | ||
| Q4 24 | 8.9% | -13.0% | ||
| Q3 24 | 24.1% | -3.0% | ||
| Q2 24 | 34.6% | -45.1% | ||
| Q1 24 | 27.1% | -36.0% |
| Q4 25 | 4.5% | 98.3% | ||
| Q3 25 | 2.8% | 55.2% | ||
| Q2 25 | 6.1% | 74.2% | ||
| Q1 25 | 6.3% | 49.0% | ||
| Q4 24 | 6.7% | 49.3% | ||
| Q3 24 | 7.2% | 41.0% | ||
| Q2 24 | 3.3% | 78.2% | ||
| Q1 24 | 5.1% | 62.2% |
| Q4 25 | 1.35× | 3.16× | ||
| Q3 25 | 3.03× | 1.31× | ||
| Q2 25 | 1.15× | 1.85× | ||
| Q1 25 | 1.39× | 2.08× | ||
| Q4 24 | 0.76× | 3.60× | ||
| Q3 24 | 1.48× | 1.78× | ||
| Q2 24 | 1.82× | 1.63× | ||
| Q1 24 | 1.28× | 2.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IDA
| Retailrevenues | $323.0M | 90% |
| Transmissionserviceswheeling | $18.6M | 5% |
| Energyefficiencyprogramrevenues | $11.7M | 3% |
| Wholesaleenergysales | $10.5M | 3% |
| Otherrevenues | $9.5M | 3% |
